| 21.32 Data as of May 17 | -0.80 / -3.62%Today’s Change | 14.07 Today|||52-Week Range 31.93 | -29.73% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Other | MARKET CAP $392.0M |
Company Description
KYTHERA Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. The company's product candidate includes ATX-10 which is an injectable drug currently in Phase III clinical development for the reduction of submental fat. Its initial focus is on the facial aesthetics market, which comprises the majority of the aesthetic medicine market. KYTHERA Biopharmaceuticals was founded by Jay Edward Birnbaum, Amit D. Munshi, Nathaniel Eames David and Keith R. Leonard, Jr. on June 3, 2004 and is headquartered in Calabasas, CA.
Employees

Shareholders
| Individual stakeholders | 49.65% |
| Other institutional | 21.07% |
| Mutual fund holders | 10.62% |
Top Executives
| Keith R. Leonard, Jr., MBA | President, Chief Executive Officer & Director |
| Jeffrey D. Webster, MBA | Senior Vice President-Operations |
| John W. Smither, CPA | Chief Financial Officer |
| Frederick Beddingfield, III, MD | Chief Medical Officer |
| Subhas Gupta, MD, PhD | Vice President-Medical Affairs |